
    
      LEAD IN: Patients receive brentuximab vedotin intravenously (IV) over 30 minutes on day 1.
      Treatment repeats every 21 days for 2 courses in the absence of disease progression or
      unacceptable toxicity.

      AVD CHEMOTHERAPY: Patients then receive doxorubicin hydrochloride IV, vinblastine IV, and
      dacarbazine IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for 6
      courses in the absence of disease progression or unacceptable toxicity.

      CONSOLIDATION: Patients achieving CR receive brentuximab vedotin IV over 30 minutes on day 1.
      Treatment repeats every 21 days for 4 courses in the absence of disease progression or
      unacceptable toxicity.

      After completion of study treatment, patients are followed up at 30 days.
    
  